Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
May 29 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 2.75 - 7.00
Open     -
Vol. 0.00
Mkt cap 138.52M
P/E     -
Div/yield     -
EPS -0.79
Shares 32.26M
Beta 2.21
Inst. own     -
May 15, 2015
Q1 2015 Aurinia Pharmaceuticals Inc Earnings Release
Mar 30, 2015
Q4 2014 Aurinia Pharmaceuticals Inc Earnings Release
Mar 2, 2015
Aurinia Pharmaceuticals Inc at Cowen Health Care Conference

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -13872.58% -5988.13%
Operating margin -8993.55% -6600.72%
EBITD margin - -5669.42%
Return on average assets -68.73% -44.07%
Return on average equity -112.32% -70.56%
Employees 26 -
CDP Score - -


1203-4464 Markham St
+1-250-7084272 (Phone)
+1-250-7442498 (Fax)

Website links


Aurinia Pharmaceuticals Inc., formerly Isotechnika Pharma Inc, is a Canada-based biopharmaceutical company focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Its lead drug, voclosporin, is an immunosuppressant effective in indications, such as prevention of rejection in renal transplantation and for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Officers and directors

Richard M. Glickman Executive Chairman of the Board
Age: 57
Stephen W. Zaruby President, Chief Executive Officer, Director
Age: 51
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Neil Solomons M.D. Chief Marketing Officer
Robert B. Huizinga Vice President - Clinical Affairs
Lawrence D. Mandt Vice President - Regulatory and Quality
Age: 57
Benjamin Rovinski Ph.D. Independent Director
Age: 58
Charles A. Rowland Jr. Independent Director
Age: 56